Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab.

Korean J Intern Med · 2023 · PMC10636556 · PMID 37867140

Europe PMC DOI

hedged sentences

0.1700

closest p · 3.4× alpha

0.1700

boldest claim

The sentences

showed a trendp = 0.170not close (p > 0.1)

They also showed that patients who relapsed early after the repopulation of peripheral blood B cells showed a trend ( p = 0.170) for a higher percentage of CD19 + CD27 + memory B cells than those who relapsed later.

also in 53,322 other papers

a decreasing trendno p-value reported

In our study, patients in group 2 showed BMD loss at the total hip at 12 months, with a decreasing trend in the OPG/RANKL ratio 12 months after rituximab treatment, unlike patients with RA treated with TNF blockers, who displayed decreased BMD in the lumbar spine, total hip, and femur [ 15 ].

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.